FDA Decision on Replimune (NASDAQ:REPL) Prompts $763 Million in Melanoma Stock Shifts
A positive FDA decision triggered the movement of nearly $763 million between two melanoma stocks on Friday. Replimune Group saw an increase of around $486 million, while Iovance Biotherapeutics lost approximately $277 million. These figures are based on the most recent common-share counts reported by the companies.